The prescription of antiplatelet medication in a very elderly population: An observational study in 15 141 ambulatory subjects

Manckoundia, Patrick; Buzens, Jean-Baptiste; Mahmoudi, Rachid; d’Athis, Philippe; Martin, Isabelle; Laborde, Caroline; Menu, Didier; Putot, Alain

doi:10.1111/ijcp.13020

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatments for cardiovascular disease are the most widely consumed drug class in the elderly population. This study shows that more than one third of a hospitalized geriatric population was on PAI, which is consistent with retrospective data obtained in an elderly French ambulatory population [26]. PAI prescription was consistent with medical history in 61.8% of patients.…”

Section: Pai In Older Patients: From Underuse To Overusesupporting

confidence: 90%

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

Laborde

Barben

Mihai

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Platelet aggregation inhibitors (PAI) have widely proven their efficiency for the prevention of ischemic cardiovascular events. We aimed to describe PAI prescription in an elderly multimorbid population and to determine the factors that influence their prescription, including the impact of age, comorbidities and frailty, evaluated through a comprehensive geriatric assessment. This cross-sectional study included all patients admitted to the acute geriatric department of a university hospital from November 2016 to January 2017. We included 304 consecutive hospitalized patients aged 88.7 ± 5.5 years. One third of the population was treated with PAI. A total of 133 (43.8%) patients had a history of cardiovascular disease, 77 of whom were on PAI. For 16 patients, no indication was identified. The prescription or the absence of PAI were consistent with medical history in 61.8% of patients. In the multivariate analysis, among the 187 patients with an indication for PAI, neither age (odds ratio (OR) = 1.00; 95% confidence interval (CI): [0.91–1.08], per year of age), nor comorbidities (OR = 0.97; 95% CI: [0.75–1.26], per point of Charlson comorbidity index), nor cognitive disorders (OR = 0.98; 95% CI [0.91–1.06] per point of Mini Mental State Examination), nor malnutrition (OR = 1.07; 95% CI [0.96–1.18], per g/L of albumin) were significantly associated with the therapeutic decision. PAI were less prescribed in primary prevention situations, in patients taking anticoagulants and in patients with a history of bleeding. In conclusion, a third of our older comorbid population of inpatients was taking PAI. PAI prescription was consistent with medical history for 61.8% of patients. Age, multimorbidity and frailty do not appear to have a significant influence on therapeutic decision-making. Further research is needed to confirm such a persistence of cardiovascular preventive strategies in frail older patients from other settings and to assess whether these strategies are associated with a clinical benefit in this specific population.

show abstract

Section: Pai In Older Patients: From Underuse To Overusesupporting

confidence: 90%

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

Laborde

Barben

Mihai

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Жүрөк-кан тамыр оорулары медициналык технологиядагы жана дарылоодогу жетишкендиктерге карабастан, дүйнө жүзү боюнча ооруканага жаткыруу жана өлүмдүн негизги себеби болуп калууда (Manckoundia et al, 2017). Атап айтканда, жүрөк-кан тамыр ооруларынын таралышы өнүккөн жана өнүгүп келе жаткан өлкөлөрдө да өсүп, аларды олуттуу глобалдык ден-соолукка тынчсыздандырууда (Ferdausi et al, 2020).…”

Section: аннотацияunclassified

“…

Cardiovascular diseases continue to be the leading cause of hospitalization and mortality worldwide, despite advancements in medical technology and treatments (Manckoundia et al, 2017). In particular, the prevalence of cardiovascular diseases is increasing in both developed and developing countries, making them a significant global health concern (Ferdausi et al, 2020).

…”

mentioning

confidence: 99%

Heart Attack: A Comparative Study of Kyrgyzstan and Indian Treatment Methods

Abdieva,

Seitova,

Chauhan

et al. 2023

ВОГУМ

View full text Add to dashboard Cite

Cardiovascular diseases continue to be the leading cause of hospitalization and mortality worldwide, despite advancements in medical technology and treatments(Manckoundia et al., 2017). In particular, the prevalence of cardiovascular diseases is increasing in both developed and developing countries, making them a significant global health concern(Ferdausi et al., 2020). Numerous risk factors contribute to cardiovascular diseases, including hypertension, diabetes, obesity, and smoking.

show abstract

Research Progress of Characterization of CYP2C19 and APOE Genes in Chronic Vascular Diseases and Their Relationship with Antiplatelet Drug

赖

2023

ACRVM

View full text Add to dashboard Cite

The prescription of antiplatelet medication in a very elderly population: An observational study in 15 141 ambulatory subjects

Cited by 4 publications

References 39 publications

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

Heart Attack: A Comparative Study of Kyrgyzstan and Indian Treatment Methods

Research Progress of Characterization of CYP2C19 and APOE Genes in Chronic Vascular Diseases and Their Relationship with Antiplatelet Drug

Contact Info

Product

Resources

About